lemtrada 12 mg 1 vial concentrado perfusión 1.2 ml
gilenya 0.5 mg capsula dura
novartis biosciences peru s.a. - droguerÍa - clorhidrato de fingolimod; - capsula dura - por capsula - - fingolimod
kiendra comprimidos recubiertos 0,25 mg (siponimod)
novartis chile s.a. - siponimod - siponimod fumarato 0,278 mg nucleo: - kiendra está indicado para el tratamiento de pacientes con esclerosis múltiple secundaria progresiva (emsp)
kiendra comprimidos recubiertos 2 mg (siponimod)
novartis chile s.a. - siponimod - siponimod fumarato 2,224 mg nucleo: - kiendra está indicado para el tratamiento de pacientes con esclerosis múltiple secundaria progresiva (emsp).
ingoly 0.5 0.5 mg capsula
accord healthcare s.a.c. - droguerÍa - capsula - por capsula - - fingolimod
emulimod 0.5mg capsula dura
varifarma peru s.a.c. - droguerÍa - capsula dura - por capsula - - fingolimod
gilenya cápsulas 0,25 mg (fingolimod)
novartis chile s.a. - fingolimod - sin formulas
gilenya 0,5 mg 28 càpsules
tysabri 300mg/15ml concentrado para solucion para perfusion
stendhal peru s.a. - droguerÍa - natalizumab - concentrado para solucion para perfusion - 300mg/15ml - por mililitro 20.00 mg - - natalizumab
tysabri
biogen netherlands b.v. - natalizumab - esclerosis múltiple - inmunosupresores selectivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.